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Presurgical Octreotide: Treatment in Acromegaly 
Ach i l le  S tevenaer t  and A lber t  Beckers  
One hundred seventy-two acromegalics who were operated on using the trans-sphenoidal approach underwent long-term 
follow-up evaluation. Sixty-four received 100 tLg octreotide subcutaneously three times daily: for 3 to 6 weeks before surgery in 
14 patients (group 1); and for 3 to 9 months in 41 and for 13 to 39 months in nine (n = 50, group 2), In 18 group 2 patients, the 
dose was increased stepwise to 500 i~g three times daily because of incomplete suppression of growth hormone 
(GH)/insulin-like growth factor-1 (IGF-1). Tumor shrinkage was seen in 60% within 3 weeks, being nearly maximal by 3 to 4 
months. More group 2 patients had greater than 25% tumor shrinkage (14 of 48 v 1 of 14 in group 1). Clinical response was 
excellent or good in 89%. Decrease in soft-tissue swelling and weight loss, and improved vitality, performance, carbohydrate 
metabolism, and cardiovascular function, facilitated anesthetic and surgical management; tumor removal was easy in virtually 
all cases. In all 64 patients, GH levels decreased by _>50%, and to <2 i~g/L in three of 14 patients initially and 25 of 50 patients 
after more prolonged treatment. IGF-1 levels decreased to normal in seven of 14 group I and 31 of 50 group 2 patients. Light and 
electron microscopy showed that adenomatous tissue exposed to octreotide had lysosomal accumulation, amyloid deposition, 
mild to moderate perivascular fibrosis, and moderate size reduction in both cytoplasmic and nuclear areas, with virtually no 
cellular complications. Remission with enclosed adenomas was greater (P < .05) than for the 108 patients not treated with 
octreotide; there was no difference for invasive adenomas. Octreotide use for 3 to 4 months before surgery can be 
recommended. 
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S URGICAL  MANAGEMENT of acromegaly is di- rected towards removing the pituitary adenoma to 
relieve compression on the pituitary gland and surrounding 
structures and normalize biochemical parameters. Results 
of trans-sphenoidal surgery have been reported in large 
series. Preoperative octreotide (a somatostatin a alog) may 
improve surgical outcome. It has been shown to improve 
clinical symptoms in the majority of acromegalic patients, to 
decrease plasma growth hormone (GH) levels to 5 p,g/L in 
almost 50% of cases, and to induce varying degrees of 
tumor shrinkage? Controlled data from large series are 
lacking; we present data from 172 acromegalic patients. 
PATIENTS AND METHODS 
The patient series consisted of 172 acromegalics (79 male and 93 
female; age range, 15 to 70 years) who were operated on using the 
trans-sphenoidal approach and underwent long-term follow-up 
evaluation (range, 0.5 to 24 years; mean. 6.4 years). Presurgieal 
octreotide treatment was given to 64 patients. Therapy was 
initiated with 100 p,g octreotide subcutaneously thrice daily and 
maintained for 3 to 6 weeks before surgery m 14 patients (group 1); 
and for 3 to 9 months in 41 and for 13 to 39 months in the remaining 
nine patients (n = 50. group 2). In 18 group 2 patients, the dose 
was iiacreased stepwise to 500 ixg thrice daily because of incomplete 
suppression fGH insulin-like growth factor-1 (IGF-1). 
Serum GH and IGF-1 levels were assayed before any treatment, 
during octreotide therapy, and after surgery. Cure of the disease 
was defined as GH levels less than 2 ixg/L and less than 1 Ixg/L 
during an oral glucose tolerance test. and IGF-1 levels within 
normal limits. 
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In patients who were given octreotide, pituitary computed 
tomographic (CT) scans and/or magnetic resonance imaging 
(MRI) were performed before octreotide treatment, after 3 weeks 
of treatment in 14 patients, and after periods ranging from 2 to 14 
months in 48 patients (two patients had no radiological controls), 
RESULTS 
The clinical response was excellent or good in 89% of 
patients. Decrease in soft-tissue swelling and weight loss, 
increased vitality and performance, amelioration of carbo- 
hydrate metabolism, and improved cardiovascular function 
facilitated anesthetic and surgical management. 
In all 64 patients, octreotide administration resulted in a 
>_50% reduction of initial GH levels (Fig 1). GH levels 
decreased to less than 2 ~g/L in three of 14 patients during 
short-term treatment and in 25 of 50 patients during more 
prolonged treatment. IGF-1 levels decreased to within 
normal imits in seven of 14 patients and 31 of 50 patients, 
respectively. 
Changes in pituitary size in the 64 patients pretreated 
with octreotide were seen in 59.7% of cases (Table 1). The 
higher dose and longer duration of pretreatmem in group 2 
patients led to an increased incidence of marked (> 25%) 
tumor shrinkage (1 of 14 v 14 of 48 in groups 1 and 2. 
respectively). 
During surgery, the adenomatous tissue was soft in 52 
cases, firm in nine, and hard in three. Tumor removal was 
easy in all cases, except hree in which the tumor was hard 
and three others in which the tumor was divided by fibrous 
septa. No noticeable changes were observed in the appar- 
ently healthy pituitary tissue. 
With light and electron microscopy, significant findings m 
adenomatous tissue exposed to octreotide were lysosomal 
accumulation, amyloid eposition, mild to moderate perivas- 
cular fibrosis, and moderate size reduction in both cytoplas- 
mic and nuclear areas. With the exception of a few cases 
with hemorrhagic necrosis, no cell necrosis, endothelial 
72 Metabolism, Vo145, No 8, Suppl 1 (August), 1996: pp 72-74 
PRESURGICAL OCTREOTIDE 73 
Fig 1. GH levelsin acromegal- 
ics treated with octreotide be- 
fore surgery, Group 1 patients 
pretreated with somatostatin for 
3 to 6 weeks; group 2 pretreated 
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injury, platelet aggregation, vascular damage, or thrombosis 
was noted. 
Surgical cure rates in the 64 pretreated patients were 
compared with those of the 108 patients who did not receive 
octreotide before surgery (Table 2). In the whole series, the 
remission rate was higher in small- and medium-sized 
(diameter <15 ram) enclosed adenomas than in large 
(diameter > 16 ram) enclosed adenomas or invasive adeno- 
mas. The incidence of remission in enclosed adenomas was 
significantly higher (P < .05) in pretreated patients than in 
untreated patients. No difference was seen in invasive 
adenomas. 
DISCUSSION 
The suppressive action of octreotide on GH secretion is 
well established, as is the resulting clinical improvement 
and pituitary adenoma shrinkage. From a surgical point of 
view, clinical improvement may facilitate anesthesia manage- 
ment and lower mortality and/o r morbidity due to surgical 
risks, allowing patients to undergo surgery and giving them 
a chance to be cured. In our series, varying degrees of 
tumor shrinkage were seen in 60% of cases. Tumor size 
reduction occurred within the first 3 weeks after octreotide 
Table 1. Pituitary Tumor Size Reduction During Octreotide Therapy 
(measured using serial CT scans and/or MRI) 
Tumor Size After Treatment Group 1 (n = 14) Group 2 (n = 50) Total (n = 64) 
No measurement 0 2 2 
No significant change 7 18 25 
Shrinkage <25% 6 16 22 
Shrinkage >25% 1 14 15 
NOTE. Group 1 pretreated for 3 to 6 weeks. Group 2 pretreated for 3 
to 39 months, 
administration and appeared as nearly maximal after 3 to 4 
months of treatment. 
The surgical outcome in acromegaly is dependent on the 
experience of the surgical team, and on the pathological 
characteristics of the pituitary adenoma, such as adenoma 
size, tissue consistency, and degree of invasiveness into the 
pituitary gland and adjacent structures. Tumor shririkage 
and softening of adenomatous tissue aided complete re- 
moval of the tumor and were probably responsible for 
better surgical outcome in oetreotide-pretreated patients 
suffering from enclosed adenomas. Recent works 2,3 have 
suggested the possibility of improved surgical results in 
invasive adenomas; however, the series have been too short 
and the criteria for biochemical cure were not severe 
enough, so that definitive conclusions could not be drawn. 
Moreover, since morphological studies 4 did not show any 
signs of cytotoxic or vascular effects of octreotide on 
adenomatous ti sue, it is unlikely to be helpful in transform- 
ing an invasive adenoma into an enclosed adenoma. 
From our experience, we conclude that presurgical oetre- 
otide treatment in acromegaly is effective in improving 
clinical condition, reducing pituitary tumor size, and soften- 
ing adenomatous tissue. These effects facilitate better 
anesthesia management and surgical procedures and im- 
prove surgical outcome. Octreotide administration for 3 tO 
4 months before surgery can be recommended. 
Table 2. Surgical Remission Rate in 172 Acromegalic Patients 
Adenoma All Cases Untreated Cases Pretreated Cases 
Grade Size (mm) No. % No, % No, % 
Enclosed _< 15 64 84 31 74 33 94 
Enclosed >_ 16 27 67 18 61 9 89 
Invasive - -  81 32 59 32 22 32 
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